Dr Andrew C Dean, PHD in Los Angeles, CA - Medicare Provider

Dr Andrew C Dean, PHD is a medicare enrolled "Clinical Neuropsychologist" provider in Los Angeles, California. His current practice location is 1654 S Orange Dr, Los Angeles, California. You can reach out to his office (for appointments etc.) via phone at (310) 825-5839.

Dr Andrew C Dean is licensed to practice in California (license number PSY21280) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1073655064.

Contact Information

	Dr Andrew C Dean, PHD
	1654 S Orange Dr, Los Angeles, CA 90019-5314
	(310) 825-5839
	(310) 825-0812

Healthcare Provider's Profile

Full Name	Dr Andrew C Dean
Gender	Male
Speciality
Experience	Years
Location	1654 S Orange Dr, Los Angeles, California
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Andrew C Dean attended and graduated from in

NPI Data:

NPI Number: 1073655064
Provider Enumeration Date: 02/13/2007
Last Update Date: 08/05/2015

Medicare PECOS Information:

PECOS PAC ID:
Enrollment ID:

Medical Identifiers

Medical identifiers for Dr Andrew C Dean such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1073655064	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103TC0700X	Psychologist - Clinical	PSY21280 (California)	Secondary
103G00000X	Clinical Neuropsychologist	PSY21280 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Andrew C Dean is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Andrew C Dean, PHD 1654 S Orange Dr, Los Angeles, CA 90019-5314 Ph: (310) 825-5839	Dr Andrew C Dean, PHD 1654 S Orange Dr, Los Angeles, CA 90019-5314 Ph: (310) 825-5839

News Archive

Allocate Software and NHS Professionals renew contract for StaffBank application

Allocate Software plc, the leading provider of workforce optimisation solutions, and NHS Professionals, the largest provider of flexible staff managed services to the NHS, are pleased to announce the renewal of a contract for the provision of the StaffBank application.

WHO research team still unsure of H7N9 transmission routes

The WHO "has only a limited understanding of a deadly new form of avian flu that has killed 20 people and infected more than a hundred others, a team of researchers said on Monday, leaving unclear how the disease spreads and how virulent it could become," the Wall Street Journal reports.

Mercator, Pepscan enter multi-program cancer research collaboration

Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration. The companies will collaborate to optimize Mercator's 'Homing Peptides' using Pepscan's proprietary CLIPS technology.

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

Celebrex may one day be used to prevent and even treat breast tumors

The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

Dr Andrew C Dean, PHD - Medicare in Los Angeles, CA